A61P 21 - Drugs for disorders of the muscular or neuromuscular system

Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
11/2002
11/28/2002	WO2002094202A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
11/28/2002	WO2002094192A2 Antibodies against tumor necrosis factor delta (april)
11/28/2002	WO2002083712A8 Transporters and ion channels
11/28/2002	WO2002078641A3 Pyrrolidine sulfonamides
11/28/2002	WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002	WO2002068652A9 Nov-x proteins and nucleic acids encoding same
11/28/2002	WO2002044153A8 4-6-diphenyl pyridine derivatives as antiinflammatory agents
11/28/2002	WO2002035235A3 Net as regulator of angiogenic expression
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2001081415A3 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	US20020178459 Genetically engineered mammal for use in the treatment of muscle and liver disorders
11/28/2002	US20020177717 Compounds and methods for the inhibition of the expression of VCAM-1
11/28/2002	US20020177609 Fatty alcohol drug conjugates
11/28/2002	US20020177591 Central nervous system (CNS); diazabicyclo compounds such as 1,4-Diaza-bicyclo(3.2.2)nonane-4-carboxylic acid, 4-cyclohexyl-phenyl ester; CNS-penetrant alpha 7 nicotinic receptor agonist
11/28/2002	US20020177586 Method for treating fibrotic diseases or other indications ID
11/28/2002	US20020177213 Tissue plasminogen activator-like protease
11/28/2002	US20020176887 Methods of delivery of cetyl myristoleate
11/28/2002	CA2448186A1 Novel smg-1
11/28/2002	CA2447671A1 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
11/28/2002	CA2447020A1 The use of 4-aminopyridine derivatives for the treatment of mglur5 receptor mediated diseases
11/28/2002	CA2446734A1 Antibodies against tumor necrosis factor delta (april)
11/28/2002	CA2445631A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	CA2444955A1 Inactivation of genes of the mep pathway
11/27/2002	EP1260229A2 Anti-autoimmune composition comprising inhibitors of growth hormone-releasing factor activity
11/27/2002	EP1259611A2 G-protein coupled receptors
11/27/2002	EP1259550A1 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
11/27/2002	EP1259504A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents
11/27/2002	EP1259493A2 Substituted piperazine compounds
11/27/2002	EP1259489A1 Aryl fused azapolycyclic compounds
11/27/2002	EP1259477A1 Aminoadamantane derivatives as therapeutic agents
11/27/2002	EP1259260A1 Combination therapy for the treatment of inflammatory and respiratory diseases
11/27/2002	EP1259223A1 Protein matrix materials, devices and methods of making and using thereof
11/27/2002	EP1192152B1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof
11/27/2002	CN1382156A PABLO polypeptide that interacts with BCL-XL and uses related thereto
11/27/2002	CN1382140A Neurotrophic pyrrolidines and piperidines and related compositions containing them
11/27/2002	CN1382136A N-heterocyclic derivatives as NOS inhibitors
11/27/2002	CN1382118A Biocyclic amino acids aspharmaceutical agents
11/27/2002	CN1382037A Oral solution containing galanthamine and sweetening agent
11/26/2002	US6486122 Methods of increasing body weight in a subject by administering TGF-α
11/26/2002	US6485745 Dosage form exhibits accelerated release of the active agent
11/21/2002	WO2002092808A1 Random gene unidirectional antisense library
11/21/2002	WO2002092807A1 Unigene unidirectional antisense library
11/21/2002	WO2002092781A2 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	WO2002092759A2 Molecules for disease detection and treatment
11/21/2002	WO2002092667A1 Biodegradable polyphosphates for controlled release of bioactive substances
11/21/2002	WO2002092563A2 Protease inhibitors
11/21/2002	WO2002092122A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/21/2002	WO2002092089A1 Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092087A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	WO2002092086A1 Imidazo (1,2-a)-pyridine derivatives as mglur5 antagonists
11/21/2002	WO2002092064A2 Therapeutic method for inducing tolerance
11/21/2002	WO2002092004A2 Use of hmg fragment as anti-inflammatory agents
11/21/2002	US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002	US20020173514 Pyridine-substituted pyrazolopyridine derivatives
11/21/2002	US20020173510 Nutrient mixture; fatty acid, calcium compound and vitamins
11/21/2002	US20020173499 Estrogen replacement therapy
11/21/2002	US20020173464 Modulation of pericyte proliferation
11/21/2002	US20020172999 Novel KIAA1061-like cell adhesion molecule-like proteins and polynucleotides encoding them
11/21/2002	US20020172661 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta (IFN-beata)
11/21/2002	CA2460603A1 Unigene unidirectional antisense library
11/21/2002	CA2447576A1 Use of hmg fragment as anti-inflammatory agents
11/21/2002	CA2447292A1 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	CA2447286A1 Random gene unidirectional antisense library
11/21/2002	CA2446879A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	CA2445366A1 Molecules for disease detection and treatment
11/21/2002	CA2443964A1 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/20/2002	EP1257646A2 Transporters and ion channels
11/20/2002	EP1257578A2 Transporters and ion channels
11/20/2002	EP1257548A1 Benzofuran carboxamides and their therapeutic use
11/20/2002	EP1257546A1 Kinase inhibitors
11/20/2002	EP1257544A2 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage
11/20/2002	EP1257277A2 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
11/19/2002	US6482832 Heterocyclically substituted amides, their production and their use
11/19/2002	US6482819 2,3-benzodiazepine derivatives
11/19/2002	CA2092821C Plant-based medicaments for increasing the tone and modulating the tone of the smooth muscular organs
11/14/2002	WO2002090530A2 Kinases and phosphatases
11/14/2002	WO2002090353A1 Sulfonamides
11/14/2002	WO2002090348A1 Sulfonamides
11/14/2002	WO2002090330A1 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives
11/14/2002	WO2002090317A1 Substituted cyclohexane-1,4-diamine derivatives
11/14/2002	WO2002089834A1 Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction
11/14/2002	WO2002089806A1 Heterobicycles fkbp-ligands
11/14/2002	WO2002089792A1 Sulfonamides
11/14/2002	WO2002089787A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	WO2002089783A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties
11/14/2002	WO2002076990A8 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
11/14/2002	WO2002018623A3 Methods and reagents for protease inhibition
11/14/2002	US20020169439 Modular infusion device and method
11/14/2002	US20020169215 Treatment of a disease that is mediated by the expression or suppression of a redox sensitive gene, for example MCP-1, IL-6 and thrombin receptor; antiinflammatory agents; cardio-vascular disorders; atherosclerosis; immunology
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169203 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169164 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
11/14/2002	US20020169156 Azacyclooctane and heptane derivatives, their preparation and use in therapy
11/14/2002	US20020169133 Treatment of diseases characterized by excessive deposits of fibrillar interstitial collagens that are resistant to proteolyic degradation thus leading to symptoms of fibrosis
11/14/2002	US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020168763 Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
11/14/2002	US20020168716 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of tumors, immunological, autoimmune, skin, viral, bone, nervous system and inflammatory disorders

1 ... 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 ... 233